Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLOVER HEALTH INVESTMENTS, CORP. /DECLOV · Entity 4419 | Director | January 06, 2025 | January 08, 2025 |
| Senior Connect Acquisition Corp. ISNRH · Entity 112401 | Director | December 10, 2020 | December 10, 2020 |
| TIVITY HEALTH, INC.TVTY · Entity 125776 | Director | February 28, 2020 | February 28, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLOVER HEALTH INVESTMENTS, CORP. /DE
Report date January 06, 2025 · Filed January 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 598,622 |
Reported balance
After 2025-01-06 transaction · row 1
1 source rowRow 1 · 2025-01-06 · Grant · Acquired 60,975 · Balance 598,622 F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of Class A common stock underlying a time-based restricted stock unit award (RSUs). The RSUs will vest in full on the first anniversary of January 6, 2025, subject to the Reporting Person's continued service as a director through such vesting date.
Senior Connect Acquisition Corp. I
Report date December 10, 2020 · Filed December 10, 2020
This filing explicitly reported no securities owned.
TIVITY HEALTH, INC.
Report date February 28, 2020 · Filed February 28, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,304 |
Reported balance
After 2020-02-28 transaction · row 1
1 source rowRow 1 · 2020-02-28 · Purchase · Acquired 4,065 · Balance 40,304 |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Livongo Health, Inc.
Report date September 11, 2020 · Filed October 30, 2020
Section 16 reporting ended · disclosed 2020-10-30. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 12,080 |
Reported balance
After 2020-09-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-09-11 · Other · Acquired 12,080 · Balance 12,080 F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2020-10-29 · Other · Disposed 1,185,097 · Balance 0 F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners. F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2020-10-29 · Other · Disposed 109,748 · Balance 0 F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners. F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2020-10-29 · Other · Disposed 176,361 · Balance 0 F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners. F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-29 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2020-10-29 · Other · Disposed 195,277 · Balance 0 F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners. F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 35,887 |
Reported balance
After 2020-10-30 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2020-10-30 · Other · Disposed 940,788 · Balance 35,887 F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners. F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 185,121 |
Reported balance
After 2020-10-30 transaction · row 10
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 10 · 2020-10-30 · Other · Acquired 173,041 · Balance 185,121 F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP. F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-30 transaction · row 13
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 13 · 2020-10-30 · Disposition to issuer · Disposed 35,887 · Balance 0 F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-10-30 transaction · row 14
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 14 · 2020-10-30 · Disposition to issuer · Disposed 185,121 · Balance 0 F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 1,693,023 |
Reported balance
After 2020-10-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-10-16 · Gift · Disposed 135,000 · Balance 1,693,023 |
| Common StockSEC Table I · non-derivative | Direct | 1,718,701 |
Reported balance
After 2020-10-29 transaction · row 7
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 7 · 2020-10-29 · Other · Acquired 25,468 · Balance 1,718,701 F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E. F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020. |
| Common StockSEC Table I · non-derivative | Direct | 1,745,807 |
Reported balance
After 2020-10-30 transaction · row 9
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 9 · 2020-10-30 · Other · Acquired 27,106 · Balance 1,745,807 F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P. |
| Common StockSEC Table I · non-derivative | Direct | 1,743,319 |
Reported balance
After 2020-10-30 transaction · row 11
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 11 · 2020-10-30 · Disposition to issuer · Disposed 2,488 · Balance 1,743,319 F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-30 transaction · row 12
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 12 · 2020-10-30 · Disposition to issuer · Disposed 1,743,319 · Balance 0 F18: Includes 763,507 RSUs. F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any). F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions). F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Wanxiang Strategic Fund I, LP.
F2: The shares are held of record by 7wire Management I, LLC. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Management I, LLC. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners.
F4: The shares were held of record by 7wire Ventures LLC - Series EosHealth. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F5: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners.
F6: The shares were held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F7: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo D without consideration to its partners.
F8: The shares were held of record by 7wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F9: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo E without consideration to its partners.
F10: The shares were held of record by 7wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F11: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures LLC - Series Livongo D and 7wire Ventures LLC - Series Livongo E.
F12: Includes 210 shares acquired under the Livongo Health, Inc. 2019 Employee Stock Purchase Plan on October 28, 2020.
F13: Represents a pro rata in-kind distribution by 7wire Ventures Fund, L.P. without consideration to its partners.
F14: The shares are held of record by 7wire Ventures Fund, L.P. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures Fund, L.P. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F15: Represents the receipt of shares pursuant to a pro rata in-kind distribution by 7wire Ventures Fund L.P.
F16: Represents the receipt of shares pursuant to pro rata in-kind distributions by 7wire Ventures Fund L.P. and 7wire Ventures Wanxiang Strategic Fund I, LP.
F17: Represents restricted stock units ("RSUs") voluntarily forfeited to the Issuer.
F18: Includes 763,507 RSUs.
F19: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 5, 2020, by and among the Issuer, Teladoc Health, Inc. ("Teladoc"), and Tempranillo Merger Sub, Inc., a wholly owned subsidiary of Teladoc, each share of the Issuer's common stock was converted into the right to receive 0.5920 of a share of Teladoc common stock and $4.24 in cash, without interest, together with cash in lieu of fractional shares (if any).
F20: Pursuant to the Merger Agreement, each outstanding RSU award of the Issuer was converted into a number of RSUs with respect to a number of shares of Teladoc common stock equal to the product of (i) the number of shares of the Issuer's common stock subject to such RSU award immediately prior to the effective time of the merger and (ii) the Equity Award Adjustment Ratio (as defined below) (rounded down to the nearest whole share of Teladoc common stock on an award-by-award basis), subject to the same terms and conditions as were applicable to such Issuer RSU immediately prior to the effective time of the merger (including applicable vesting conditions).
F21: The "Equity Award Adjustment Ratio" means the quotient determined by dividing (i) the volume weighted average closing price of the Issuer's common stock on the four trading days ending on October 29, 2020 by (ii) the volume weighted average closing price of Teladoc common stock on the four trading days beginning on October 29, 2020.
Medidata Solutions, Inc.
Report date October 28, 2019 · Filed October 28, 2019
Section 16 reporting ended · disclosed 2019-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 1
1 source rowRow 1 · 2019-10-28 · Disposition to issuer · Disposed 28,827 · Balance 0 F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger"). F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2021-05-31 | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-10-28 · Disposition to issuer · Disposed 4,494 · Balance 0 F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4: These options are fully vested and exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2022-05-16 | Direct | 0 |
Reported balance
After 2019-10-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-28 · Disposition to issuer · Disposed 5,214 · Balance 0 F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4: These options are fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger").
F2: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration").
F3: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option.
F4: These options are fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 93,790 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 4 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 191,341 F3 · kind: Represents a pro rata in-kind distribution by 7wire Ventures LLC - Series Livongo C without consideration to its partners (including 7wire LP). F4 · ownership.nature: The shares are held of record by 7wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7wire Management, the Manager of 7wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| April 09, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | OtherCommon Stock | 1,307,682 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,066,305 F1 · kind: Represents a pro rata in-kind distribution by 7wire Ventures, LLC - Series EosHealth without consideration to its partners (including 7wire Ventures Fund, L.P., or 7wire LP). F2 · ownership.nature: The shares are held of record by 7wire Ventures LLC-Series EosHealth. The reporting person serves as a Manager of 7wire Management, LLC, or 7wire Management, the Manager of 7wire Ventures LLC-Series EosHealth. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 18:00 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 1,322 | $23.00 | $30,406.00 |
DisclosureSEC source: 0001209191-20-020322 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,852,900 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| March 06, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GiftCommon Stock | 4,190 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,848,330 Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 18:08 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 13,347 | $27.94 | $372,977.91 |
DisclosureSEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,854,222 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.80 to $28.04, inclusive. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 18:08 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 12,606 | $27.52 | $346,978.89 |
DisclosureSEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,867,569 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.80 to $27.79, inclusive. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 18:08 UTC | Livongo Health, Inc. LVGO · Entity 145566 | SaleCommon Stock | 1,547 | $26.36 | $40,775.36 |
DisclosureSEC source: 0001209191-20-017444 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,880,175 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2019. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.72 to $26.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 16:30 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | PurchaseCommon Stock | 4,065 | $12.00 | $48,780.00 |
DisclosureSEC source: 0001567619-20-005132 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,304 Read SEC document |
| February 20, 2020 Filed Apr 13, 2020 19:22 UTC | Livongo Health, Inc. LVGO · Entity 145566 | GiftCommon Stock | 380 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-010679 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,852,520 Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 17:30 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 818 | $26.93 | $22,028.74 |
DisclosureSEC source: 0001209191-20-010723 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,881,722 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 20:51 UTC | Livongo Health, Inc. LVGO · Entity 145566 | Tax withholdingCommon Stock | 102,325 | $28.90 | $2,957,192.50 |
DisclosureSEC source: 0001209191-20-004764 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,882,540 F1 · kind: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. F1 · shares: The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs. Read SEC document |
| October 28, 2019 Filed Oct 28, 2019 16:33 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | Disposition to issuerStock Option (right to buy) · Derivative | 5,214 | Not disclosed Strike: $13.98 | Not disclosed |
DisclosureSEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · derivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,214 shares Expires 2022-05-16 F3 · shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F3 · price: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4 · derivative.exercise_date: These options are fully vested and exercisable. Read SEC document |
| October 28, 2019 Filed Oct 28, 2019 16:33 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | Disposition to issuerStock Option (right to buy) · Derivative | 4,494 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · derivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,494 shares Expires 2021-05-31 F3 · shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F3 · price: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. F4 · derivative.exercise_date: These options are fully vested and exercisable. F3 · derivative.underlying_shares: Pursuant to the Merger Agreement and by virtue of the Merger, each option to purchase Issuer Common Stock will be cancelled and converted into the right to receive an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the total number of shares of Issuer Common Stock then covered by such option multiplied by (2) the excess, if any, of $92.25 per share over the exercise price per share under such option. Read SEC document |
| October 28, 2019 Filed Oct 28, 2019 16:33 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | Disposition to issuerCommon Stock | 28,827 | $92.25 | $2,659,290.75 |
DisclosureSEC source: 0001453814-19-000149 · wf-form4_157229477150358.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On October 28, 2019, pursuant to the Agreement and Plan of Merger, dated as of June 11, 2019, by and among Dassault Systemes SE ("DS"), Dassault Systemes Americas Corp., a Delaware corporation ("Parent"), 3DS Acquisition 6 Corp., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), and Medidata Solutions, Inc., a Delaware corporation (the "Issuer"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent and an indirect wholly-owned subsidiary of DS (the "Merger"). F2 · shares: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration"). F2 · price: Disposed of pursuant to the Merger Agreement and by virtue of the Merger, in which each share of Medidata common stock, par value $0.01 per share ("Issuer Common Stock"), issued and outstanding immediately prior to the completion of the Merger (other than restricted share awards held by continuing employees) was converted into the right to receive $92.25 in cash and without interest (the "Merger Consideration"). Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries E Convertible Preferred Stock · Derivative | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 15 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries E Convertible Preferred Stock · Derivative | 400,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 14 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 400,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries E Convertible Preferred Stock · Derivative | 488,683 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 13 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 488,683 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.exercise_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · derivative.expiration_date: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries D Convertible Preferred Stock · Derivative | 361,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 12 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 361,718 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries D Convertible Preferred Stock · Derivative | 250,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 11 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 250,800 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.exercise_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · derivative.expiration_date: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries C Convertible Preferred Stock · Derivative | 285,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 10 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 285,131 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,104 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 9 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 2,104 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionSeries A Convertible Preferred Stock · Derivative | 3,506 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · derivative · entry 8 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 0 Underlying: Common Stock · 3,506 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 60,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 5 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 60,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F9 · ownership.nature: The shares are held of record by 7Wire Ventures Wanxiang Strategic Fund I, LLC, or 7Wire Wanxiang. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Wanxiang. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 400,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 4 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 400,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F8 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo E. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo E. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 361,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 3 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 361,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F6 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo D. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo D. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 285,131 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 285,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · ownership.nature: The shares are held of record by 7Wire Ventures LLC - Series Livongo C. The reporting person serves as a Manager of 7Wire Management, the Manager of 7Wire Ventures LLC - Series Livongo C. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 16:32 UTC | Livongo Health, Inc. LVGO · Entity 145566 | ConversionCommon Stock | 745,093 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-020582 · doc4.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote. Disclosed balance after: 1,159,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F5 · price: Each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F7 · price: Each share of Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · ownership.nature: The shares are held of record by 7Wire Ventures Fund, L.P., or 7Wire LP. The reporting person serves as a Manager of 7Wire Management, LLC, or 7Wire Management, the Manager of 7Wire LP. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 29, 2019 Filed May 30, 2019 16:55 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GrantCommon Stock | 2,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-19-000089 · wf-form4_155924972328476.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,827 F1 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 29, 2020. F2 · price: Granted as compensation for services. Read SEC document |
| May 23, 2019 Filed May 28, 2019 15:07 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 6,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012201 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,239 F1 · shares: Reflects restricted stock units that vest on the earlier of (i) the first anniversary of the Grant Date (such Grant Date being 5/23/2019), or (ii) the first annual meeting of the stockholders of Tivity Health that occurs after the Grant Date. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 15:00 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | PurchaseCommon Stock | 4,050 | $17.80 | $72,090.00 |
DisclosureSEC source: 0001567619-19-007451 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,141 Read SEC document |
| July 26, 2018 Filed Jul 26, 2018 17:13 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | SaleCommon Stock | 12,500 | $76.16 | $952,000.00 |
DisclosureSEC source: 0001453814-18-000108 · wf-form4_153263957212902.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,028 F1 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2018. F2 · price: Such transaction was executed in multiple trades at prices ranging from $75.39 to $77.32. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 30, 2018 Filed May 31, 2018 16:24 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GrantCommon Stock | 3,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-18-000088 · wf-form4_152779828058021.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,528 F2 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 30, 2019. F3 · price: Granted as compensation for services. Read SEC document |
| May 24, 2018 Filed May 25, 2018 13:05 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 2,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-025695 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,091 F1 · shares: Reflects restricted stock units that vest on the earlier of (i) the first anniversary of the Grant Date (such Grant Date being 5/24/2018), or (ii) the first annual meeting of the stockholders of Tivity Health that occurs after the Grant Date. Read SEC document |
| March 05, 2018 Filed May 31, 2018 16:24 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-18-000088 · wf-form4_152779828058021.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,467 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| November 28, 2017 Filed Feb 13, 2018 16:46 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 59 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-18-000006 · wf-form5_151855832283551.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,842 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| November 27, 2017 Filed Feb 13, 2018 16:46 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 364 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-18-000006 · wf-form5_151855832283551.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,901 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 16:44 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GrantCommon Stock | 3,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-17-000091 · wf-form4_149634984881074.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,265 F2 · shares: Represents shares of restricted stock. The restrictions will lapse in full on May 30, 2018. F3 · price: Granted as compensation for services. Read SEC document |
| May 25, 2017 Filed May 30, 2017 10:56 UTC | TIVITY HEALTH, INC. TVTY · Entity 125776 | GrantCommon Stock | 3,012 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022650 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,215 F1 · shares: Reflects restricted stock units that vest on 5/25/2018. Read SEC document |
| February 14, 2017 Filed Jun 1, 2017 16:44 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 644 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-17-000091 · wf-form4_149634984881074.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,931 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| December 16, 2016 Filed Feb 14, 2017 17:41 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-17-000008 · wf-form5_148711202004438.xml · nonDerivative · entry 2 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,575 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| December 15, 2016 Filed Feb 14, 2017 17:41 UTC | Medidata Solutions, Inc. MDSO · Entity 154211 | GiftCommon Stock | 992 | $0.00 | $0.00 |
DisclosureSEC source: 0001453814-17-000008 · wf-form5_148711202004438.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,317 F1 · price: Bona fide gift by the Reporting Person for no consideration. Read SEC document |
| November 04, 2016 Filed Nov 7, 2016 14:00 UTC | TIVITY HEALTH, INC. HWAY · Entity 125776 | PurchaseCommon Stock | 1,266 | $19.53 | $24,724.98 |
DisclosureSEC source: 0001140361-16-085028 · doc1.xml · nonDerivative · entry 1 SHAPIRO LEE · CIK 0001213350 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,203 F1 · price: This transaction was executed in multiple trades at prices ranging from $19.50 to $19.55. The price reported above reflects the weighted-average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.